Niels Risum

Niels Risum

Auto-generated profile, based on publicly available information

Niels Risum

Department of Cardiology, The Heart Centre, Copenhagen University Hospital—Rigshospitalet , Copenhagen

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in JMIR Human Factors
Verified
Journal Article
Open access
SMStina Matthiesen
Stina Matthiesen
SDSøren Zöga Diederichsen
Søren Zöga Diederichsen
MHMikkel Klitzing Hartmann Hansen
Mikkel Klitzing Hartmann Hansen
CVChristina Villumsen
Christina Villumsen
MLMats Christian Højbjerg Lassen
Mats Christian Højbjerg Lassen
TATariq Osman Andersen
Tariq Osman Andersen
Background: Artificial intelligence (AI), such as machine learning (ML), shows great promise for improving clinical decision-making in cardiac diseases by outperforming statistical-based models. However, few AI-based tools have been implemented in cardiology clinics because of the sociotechnical challenges during transitioning from algorithm development to real-world implementation. Objective: This study explored how an ML-based tool for predicting ventricular tachycardia and ventricular fibrillation (VT/VF) could support clinical decision-making in the remote monitoring of patients with an implantable cardioverter defibrillator (ICD). Methods: Seven experienced electrophysiologists participated in a near-live feasibility and qualitative study, which included walkthroughs of 5 blinded retrospective patient cases, use of the prediction tool, and questionnaires and interview questions. All sessions were video recorded, and sessions evaluating the prediction tool were transcribed verbatim. Data were analyzed through an inductive qualitative approach based on grounded theory. Results: The prediction tool was found to have potential for supporting decision-making in ICD remote monitoring by providing reassurance, increasing confidence, acting as a second opinion, reducing information search time, and enabling delegation of decisions to nurses and technicians. However, the prediction tool did not lead to changes in clinical action and was found less useful in cases where the quality of data was poor or when VT/VF predictions were found to be irrelevant for evaluating the patient. Conclusions: When transitioning from AI development to testing its feasibility for clinical implementation, we need to consider the following: expectations must be aligned with the intended use of AI; trust in the prediction tool is likely to emerge from real-world use; and AI accuracy is relational and dependent on available information and local workflows. Addressing the sociotechnical gap between the development and implementation of clinical decision-support tools based on ML in cardiac care is essential for succeeding with adoption. It is suggested to include clinical end-users, clinical contexts, and workflows throughout the overall iterative approach to design, development, and implementation.

15 April 2016 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
TBTor Biering-Sørensen
Tor Biering-Sørensen
FOFlemming Javier Olsen
Flemming Javier Olsen
KSKatrine Storm
Katrine Storm
TFThomas Fritz-Hansen
Thomas Fritz-Hansen
NONiels Thue Olsen
Niels Thue Olsen
NRNiels Risum
Niels Risum
Only 30% of patients receiving an implantable cardioverter defibrillator (ICD) for primary prevention receive appropriately therapy. We sought to investigate the value of tissue Doppler imaging (TDI) to predict ventricular tachycardia (VT), ventricular fibrillation (VF), and cardiovascular mortality (CVD) in patients with primary prevention ICD. In total, 151 ICD patients meeting primary prevention criteria and with no history of ventricular arrhythmias were included. All participants were examined by conventional 2D echocardiography and TDI echocardiography. Longitudinal systolic ( s ′), early diastolic ( e ′), and late diastolic ( a ′) myocardial velocities were measured using TDI at six mitral annular sites and averaged to provide global estimates. Forty patients experienced the combined endpoint of VT, VF, or CVD during a median follow-up of 2.3 years. Left ventricular ejection fraction, global longitudinal strain, E / e ′, global s ′, and global e ′ were not significantly different in patients who developed VT/VF/CVD compared with those who did not. In contrast, global a ′ was significantly lower in patients with an unfavourable outcome compared with those without (4.8 ± 2.0 vs. 5.7 ± 1.8 cm/s, P = 0.020). Global a ′ remained an independent predictor of VT/VF/CVD after multivariable adjustment for age, gender, β-blocker therapy, and deceleration time (HR = 1.25 [1.02, 1.54], P = 0.032). Regional analysis revealed that a depressed a ′ in the inferior wall drives the predictive capability of a ′. Late diastolic velocity by TDI seems to be a superior echocardiographic predictor of VT/VF/CVD in ischaemic cardiomyopathy. Additionally, impaired late diastolic velocity in the inferior myocardial wall seems to be a paramount marker of future VT/VF/CVD.

1 December 2015 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
BTBhupendar Tayal
Bhupendar Tayal
JGJohn Gorcsan
John Gorcsan
ADAntonia Delgado-Montero
Antonia Delgado-Montero
JMJosef J. Marek
Josef J. Marek
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
PSPeter Søgaard
Peter Søgaard

27 February 2021 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
PDF file
MWMik Wetterslev
Mik Wetterslev
PJPeter Karl Jacobsen
Peter Karl Jacobsen
CHChristian Hassager
Christian Hassager
CJChristian Jøns
Christian Jøns
NRNiels Risum
Niels Risum
APAnders Perner
Anders Perner
Background: Coronavirus disease 2019 (COVID‐19) may be associated with cardiac arrhythmias in hospitalized patients, but data from the ICU setting are limited. We aimed to describe the epidemiology of cardiac arrhythmias in ICU patients with COVID‐19.Methods: We conducted a multicenter, retrospective cohort study including all ICU patients with an airway sample positive for severe acute respiratory syndrome corona‐virus 2 from March 1st to June 1st in the Capital Region of Denmark (1.8 million inhabitants). We registered cardiac arrhythmias in ICU, potential risk factors, interventions used in ICU and outcomes.Results: From the seven ICUs we included 155 patients with COVID‐19. The incidence of cardiac arrhythmias in the ICU was 57/155 (37%, 95% confidence interval 30‐45), and 39/57 (68%) of these patients had this as new‐onset arrhythmia. Previous history of tachyarrhythmias and higher disease severity at ICU admission were associated with cardiac arrhythmias in the adjusted analysis. Fifty‐four of the 57 (95%) patients had supraventricular origin of the arrhythmia, 39/57 (68%) received at least one intervention against arrhythmia (eg amiodarone, IV fluid or magnesium) and 38/57 (67%) had recurrent episodes of arrhythmia in ICU. Patients with arrhythmias in ICU had higher 60‐day mortality (63%) as compared to those without arrhythmias (39%).Conclusion: New‐onset supraventricular arrhythmias were frequent in ICU patients with COVID‐19 and were related to previous history of tachyarrhythmias and severity of the acute disease. The mortality was high in these patients despite the frequent use of interventions against arrhythmias.

1 August 2024 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
PDF file
DFDiana My Frodi
Diana My Frodi
MKMaarten Z H Kolk
Maarten Z H Kolk
JLJoss Langford
Joss Langford
RKReinoud Knops
Reinoud Knops
HTHanno L. Tan
Hanno L. Tan
SDSøren Zöga Diederichsen
Søren Zöga Diederichsen
Aims: Wearable health technologies are increasingly popular. Yet, wearable monitoring only works when devices are worn as intended, and adherence reporting lacks standardization. In this study, we aimed to explore the long-term adherence to a wrist-worn activity tracker in the prospective SafeHeart study and identify patient characteristics associated with adherence. Methods and results: This study enrolled 303 participants, instructed to wear a wrist-worn accelerometer day and night for 6 months. Long-term adherence was defined as valid days (≥22 h of wear time) divided by expected days, and daily adherence as mean hours of wear time per 24 h period. Optimal, moderate, and low long-term and daily adherence groups were defined as long-term adherence above or below 95 and 75% and daily adherence above or below 90 and 75%. Regression models were used to identify patient characteristics associated with long-term adherence. In total, 296 participants [median age 64 years; interquartile range (IQR) 57–72; 19% female] were found eligible, yielding 44 003 days for analysis. The median long-term adherence was 88.2% (IQR 74.6–96.5%). A total of 83 (28%), 127 (42.9%), and 86 (29.1%) participants had optimal, moderate, and low long-term adherence, and 163 (55.1%), 87 (29.4%), and 46 (15.5%) had optimal, moderate, and low daily adherence, respectively. Age and smoking habits differed significantly between adherence levels, and increasing changeover intervals improved the degree of long-term adherence. Conclusion: Long-term adherence to a wearable activity tracker was 88.2% over a 6-month period. Older age and longer changeover interval were positively associated with long-term adherence. This serves as a benchmark for future studies that rely on wearable devices. Trial registration number: The National Trial Registration number: NL9218 (https://onderzoekmetmensen.nl/).

1 April 2004 in Current Vascular Pharmacology
Verified
Journal Article
Closed access
PDF file
RBR. Boushel
R. Boushel
HLH. Langberg
H. Langberg
NRN. Risum
N. Risum
MKM. Kjaer
M. Kjaer
Prostaglandins (PGs) belong to the family of prostanoids together with thromboxanes and are produced mainly from arachadonic acid by the enzyme cyclooxygenase. PGs are known to stimulate platelet aggregation, mediate inflammation and edema, play a role in bone metabolism and in biological adaptation of connective tissues e.g. tendon. This review covers the role of PG for mediating tissue blood flow at rest and during increases in metabolic demand such as exercise and reactive hyperaemia. There is strong evidence that PGs contribute to elevate blood flow at rest and during reactive hyperaemia in a variety of tissues. Their role for regulating the large increases in muscle blood flow during exercise is less clear which may be explained by redundant mechanisms. Several interactions are known to exist between specific vasodilator substances, and therefore PGs can act in synergy with other substances and contribute to functional hyperaemia. Furthermore, there is evidence for differential, tissue-specific influences of PGs where their influence on blood flow during exercise may be profound.